Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | ABL1 | P00519 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | IDE | P14735 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | CA12 | O43570 | 6/20 | 0.60 |
| ▸ | CA1 | P00915 | 6/20 | 0.60 |
| ▸ | CA2 | P00918 | 6/20 | 0.60 |
| ▸ | CA9 | Q16790 | 6/20 | 0.60 |
| ▸ | HLCS | P50747 | 4/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8819529 | 0.98 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13110899 | 0.89 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13185305 | 0.89 | FOLH1 (0.63) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL9412852 | 0.89 | TDP1 (0.74) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL9174298 | 0.88 | TDP1 (0.79) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12606268 | 0.88 | TDP1 (0.79) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL18268949 | 0.88 | TDP1 (0.79) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL25417015 | 0.87 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL10171661 | 0.87 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL16913029 | 0.87 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113896762-B | Liquid phase synthesis method of biotin tripeptide-1 | 浙江湃肽生物有限公司深圳分公司 | 2022-03-29 | — | — | CN | claimed |
| CN-119470877-A | Biotinylation modified amino acid probe, preparation method and application thereof, and method and application for identifying amino acid binding protein | 同济大学 | 2025-02-18 | — | — | CN | disclosed |
| US-20230285464-A1 | NOVEL CELLULAR RECEPTORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-09-14 | — | — | US | disclosed |
| US-11672828-B2 | Cellular receptors and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-06-13 | — | — | US | disclosed |
| CN-113896762-B | Liquid phase synthesis method of biotin tripeptide-1 | 浙江湃肽生物有限公司深圳分公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-113896762-B | Liquid phase synthesis method of biotin tripeptide-1 | 浙江湃肽生物有限公司深圳分公司 | 2022-03-29 | — | — | CN | disclosed |
| WO-2021163018-A1 | NOVEL CELLULAR RECEPTORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20210244764-A1 | NOVEL CELLULAR RECEPTORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2021-08-12 | — | — | US | disclosed |
| EP-2755667-A2 | METHOD FOR ENHANCING THE GROWTH AND FULLNESS OF HAIR | Avon Products, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013039597-A2 | METHOD FOR ENHANCING THE GROWTH AND FULLNESS OF HAIR | AVON PRODUCTS, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20030228254-A1 | Diagnosis of cardiovascular disorders | AMERSHAM HEALTH AS (NO) | 2003-12-11 | — | — | US | disclosed |
| US-6524552-B2 | Imaging cardiovascular disorders | GE HEALTHCARE AS (NO) | 2003-02-25 | — | — | US | disclosed |
| US-20010016587-A1 | Contrast agents | NYCOMED IMAGING AS | 2001-08-23 | — | — | US | disclosed |
| EP-1007101-A2 | IMPROVEMENTS IN OR RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS | Marsden, John Christopher (GB) | 2000-06-14 | — | — | EP | disclosed |
| EP-0973552-A2 | IMPROVEMENTS IN OR RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS | Marsden, John Christopher (GB) | 2000-01-26 | — | — | EP | disclosed |
| EP-0971747-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 2000-01-19 | — | — | EP | disclosed |
| CN-1238700-A | Improvements in or relating to diagnostic and/or therapeutic agents | NYCOMED IMAGING AS (NO) | 1999-12-15 | — | — | CN | disclosed |
| WO-1998018496-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-05-07 | — | — | WO | disclosed |
| WO-1998018500-A2 | IMPROVEMENTS IN OR RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS | MARSDEN, JOHN, CHRISTOPHER (GB) | 1998-05-07 | — | — | WO | disclosed |
| WO-1998018501-A2 | IMPROVEMENTS IN OR RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS | MARSDEN, JOHN, CHRISTOPHER (GB) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244764-A1 | NOVEL CELLULAR RECEPTORS AND USES THEREOF | SRPRA, CACYBP, SRPRB | TDP1 3400/4885MEN1 4246/4885ABL1 4564/4885 |
| US-11672828-B2 | Cellular receptors and uses thereof | SRPRA, NPBWR1, BCAP31 | TDP1 3462/4885MEN1 3868/4885ABL1 4348/4885 |
| US-20030228254-A1 | Diagnosis of cardiovascular disorders | AGTR1, AGTR2, AGT | TDP1 4049/4885MEN1 693/4885ABL1 1544/4885 |
| US-20010016587-A1 | Contrast agents | AGTR1, AGTR2, VIPR1 | TDP1 4074/4885MEN1 386/4885ABL1 1453/4885 |
| US-20230285464-A1 | NOVEL CELLULAR RECEPTORS AND USES THEREOF | SRPRA, CACYBP, SRPRB | TDP1 3400/4885MEN1 4246/4885ABL1 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.